BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 15308278)

  • 1. Beta-lactam antibiotics: newer formulations and newer agents.
    Martin SI; Kaye KM
    Infect Dis Clin North Am; 2004 Sep; 18(3):603-19, ix. PubMed ID: 15308278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of different resistance traits on the competitive growth of Haemophilus influenzae in antibiotic-free medium and selection of resistant populations by different {beta}-lactams: an in vitro pharmacodynamic approach.
    González N; Aguilar L; Alou L; Giménez MJ; Sevillano D; Torrico M; Cafini F; Coronel P; Prieto J
    J Antimicrob Chemother; 2009 Jun; 63(6):1215-22. PubMed ID: 19307171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Part II. Introduction to the beta-lactam antibiotics.
    Cooper TW; Gibbs WJ; Bronze MS; Greenfield RA
    J Okla State Med Assoc; 2006 Oct; 99(10):516-20. PubMed ID: 17125105
    [No Abstract]   [Full Text] [Related]  

  • 4. [Beta-lactam antibiotics].
    Suárez C; Gudiol F
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):116-29. PubMed ID: 19254642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. beta-Lactams without a suicide inhibitor.
    Giamarellou H
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():194-7. PubMed ID: 18154547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are beta-lactam breakpoints adequate to define non-susceptibility for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view?
    Alou L; Giménez MJ; Sevillano D; Aguilar L; González N; Echeverría O; Torrico M; Coronel P; Prieto J
    J Antimicrob Chemother; 2007 Apr; 59(4):652-7. PubMed ID: 17341471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction: historical perspective and development of amoxicillin/clavulanate.
    Geddes AM; Klugman KP; Rolinson GN
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S109-12. PubMed ID: 17900874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pseudomonas aeruginosa and beta-lactam antibiotics at the time of Europe].
    Cavallo JD; Mérens A
    Pathol Biol (Paris); 2008; 56(7-8):435-8. PubMed ID: 19019568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redefining penems.
    Dalhoff A; Janjic N; Echols R
    Biochem Pharmacol; 2006 Mar; 71(7):1085-95. PubMed ID: 16413506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriate prescribing of oral beta-lactam antibiotics.
    Holten KB; Onusko EM
    Am Fam Physician; 2000 Aug; 62(3):611-20. PubMed ID: 10950216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime.
    Bazan JA; Martin SI; Kaye KM
    Infect Dis Clin North Am; 2009 Dec; 23(4):983-96, ix. PubMed ID: 19909894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles.
    Jacobs MR
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):353-60. PubMed ID: 15954852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral carbapenems.
    Shah PM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Part V. Other beta-lactam antimicrobials.
    Gibbs WJ; Cooper TW; Bronze MS; Greenfield RA
    J Okla State Med Assoc; 2007 Jan; 100(1):23-5. PubMed ID: 17378498
    [No Abstract]   [Full Text] [Related]  

  • 17. Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases.
    Bedenic B; Vranes J; Suto S; Zagar Z
    Int J Antimicrob Agents; 2005 Jun; 25(6):479-87. PubMed ID: 15894465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trial.
    Poachanukoon O; Kitcharoensakkul M
    Clin Ther; 2008 Oct; 30(10):1870-9. PubMed ID: 19014842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nontraditional beta-lactam antibiotics].
    Vanderhaeghe H
    Verh K Acad Geneeskd Belg; 1991; 53(1):39-58; discussion 58-9. PubMed ID: 2053420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media.
    Fenoll A; Aguilar L; Robledo O; Giménez MJ; Tarragó D; Granizo JJ; Gimeno M; Coronel P
    J Antimicrob Chemother; 2007 Aug; 60(2):323-7. PubMed ID: 17562681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.